Defective metabolism of Leukotriene B4 in the Sjögren–Larsson Syndrome

[1]  A. Heerschap,et al.  5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-Larsson syndrome. , 2000, Neuropediatrics.

[2]  E. Mayatepek,et al.  Defective inactivation of leukotriene B4 in patients with Sjögren-Larsson syndrome. , 2000, The Journal of pediatrics.

[3]  W. Rizzo,et al.  The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. , 1999, American journal of human genetics.

[4]  F. Gabreëls,et al.  Preterm birth in Sjögren-Larsson syndrome. , 1999, Neuropediatrics.

[5]  P. Devillier,et al.  Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. , 1999, Pharmacological research.

[6]  F. Gabreëls,et al.  Sjögren–Larsson syndrome , 1999, Neurology.

[7]  H. von Giesen,et al.  LTB4 and LTC4 are absent in the cerebrospinal fluid of human immunodeficiency virus type 1-seropositive persons with toxoplasmic encephalitis: evidence for inhibition of 5-lipoxygenase by Toxoplasma gondii. , 1999, The Journal of infectious diseases.

[8]  E. Israel,et al.  Correction: Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. , 1999, The New England journal of medicine.

[9]  E. Mayatepek,et al.  Leukotriene C4-synthesis deficiency: a new inborn error of metabolism linked to a fatal developmental syndrome , 1998, The Lancet.

[10]  I. Rodger,et al.  Leukotrienes and the brain , 1998, The Lancet.

[11]  Y. Kuraishi,et al.  Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. , 1998, European journal of pharmacology.

[12]  W. Rizzo,et al.  Involvement of microsomal fatty aldehyde dehydrogenase in the α‐oxidation of phytanic acid , 1998 .

[13]  R. Zoeller,et al.  Isolation of Animal Cell Mutants Defective in Long-chain Fatty Aldehyde Dehydrogenase* , 1997, The Journal of Biological Chemistry.

[14]  A. Zicari,et al.  Effects of glucocorticoids and progesterone on prostaglandin E2 and leukotriene B4 release by human fetal membranes at term gestation. , 1997, Prostaglandins.

[15]  W. Rizzo,et al.  Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. , 1997, Biochimica et biophysica acta.

[16]  T. Masuyama,et al.  Leukotriene B4 and C4 in cerebrospinal fluid from children with meningitis and febrile seizures. , 1996, Pediatric neurology.

[17]  W. Rizzo.  Sjögren-Larsson syndrome. , 1993, Seminars in dermatology.

[18]  W. Lehmann,et al.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders. , 1992 .

[19]  W. Rizzo,et al.  Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts. , 1991, The Journal of clinical investigation.

[20]  J. Maclouf,et al.  Development of enzyme immunoassays for leukotrienes using acetylcholinesterase. , 1991, Biochimica et biophysica acta.

[21]  T. Simmet,et al.  Lipoxygenase products of polyunsaturated fatty acid metabolism in the central nervous system: biosynthesis and putative functions. , 1990, Pharmacological research.

[22]  D. Keppler,et al.  Inhibition of leukotriene ?-oxidation by ?-trifluoro analogs of leukotrienes , 1990 .

[23]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[24]  J. Keeling,et al.  Placental leukotriene B4 release in early pregnancy and in term and preterm labour. , 1990, Early human development.

[25]  T. Simmet,et al.  Formation of cysteinyl-leukotrienes by human brain tissue , 1988, Brain Research.

[26]  Sumimoto Hideki,et al.  NAD+-dependent oxidation of 20-hydroxyleukotriene B4 to 20-carboxyleukotriene B4 by rat liver cytosol , 1988 .

[27]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[28]  E. Goetzl,et al.  Role of concentrative leukotriene transport systems in the central nervous system. , 1986, Biochemical pharmacology.

[29]  S. Shak,et al.  Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. , 1984, The Journal of biological chemistry.

[30]  E. Goetzl,et al.  Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. , 1984, Science.

[31]  J. Oates,et al.  Metabolism of leukotriene B4 in the monkey. Identification of the principal nonvolatile metabolite in the urine. , 1984, Prostaglandins.

[32]  F. Horner.  Oligophrenia in Combination with Congenital Ichthyosis and Spastic Disorders , 1959 .

[33]  E. Mayatepek,et al.  Leukotrienes: Biosynthesis, Metabolism, and Pathophysiologic Significance , 1995, Pediatric Research.

[34]  A. Böyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.